Carnitine palmitoyltransferase IA polymorphism P479L is common in Greenland Inuit and is associated with elevated plasma apolipoprotein A-I

• Published in: Journal of Lipid Research
• Main Authors: Rajakumar, Chandheeb, Ban, Matthew R., Cao, Henian, Young, T. Kue, Bjerregaard, Peter, Hegele, Robert A.
• Format: Text
• Language: English
• Published: American Society for Biochemistry and Molecular Biology 2009
• Subjects: Patient-Oriented and Epidemiological Research; Greenland; inuit
• Online Access: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2681405; http://www.ncbi.nlm.nih.gov/pubmed/19181627; https://doi.org/10.1194/jlr.P900001-JLR200

Carnitine palmitoyltransferase IA, encoded by CPT1A, is a key regulator of fatty acid metabolism. Previously, a loss-of-function mutation, namely, c.1436 C→T (p.P479L), was reported in CPT1A in the homozygous state in Canadian aboriginal male with presumed CPT1A deficiency. To determine the population frequency of this variant, we determined CPT1A p.P479L genotypes in 1111 Greenland Inuit. Associations between genotype and variation in plasma total cholesterol, triglycerides, LDL, HDL, apolipoprotein (apo) B, and apoA-I was also investigated. We found the L479 allele occurs at a high frequency in this sample (0.73), while it was completely absent in 285 nonaboriginal samples. This suggests that the original proband's symptoms were not likely due to the CPT1A p.P479L mutation because it is very common in Inuit and because symptoms suggesting CPT1A deficiency have not been reported in any carrier subsequently studied. However, CPT1A p.P479L was associated with elevated plasma HDL and apoA-I levels. The association with increased levels of HDL and apoA-I suggest that the polymorphism might protect against atherosclerosis.